European Council Outlines Goals to Target Chronic Disease


Ministers for health adopted conclusions from the Council of the European Union on chronic diseases.

The European League Against Rheumatism (EULAR) welcomes the outcomes of the Council of the European Union (EPSCO Council). Ministers for health adopted conclusions from the Council of the European Union (EPSCO Council) on chronic diseases.

The conclusions call on Member States and the European Commission to adopt concrete, coordinated measures to tackle chronic diseases in Europe. In a press release, EULAR stated it is pleased to note that the Council Conclusions reflect many of the recommendations made at the 19 October Presidency conference on Rheumatic and Musculoskeletal diseases. The conference was organized jointly by the Presidency and EULAR.

Profesor Paul Emery (EULAR president) highlighted the "political relevance of the Council Conclusions", as the Council's position "represents a clear message in favour of concrete initiatives at both EU and national levels, to address chronic diseases. This is particularly important for those disorders which represent a huge burden on our economies and health systems, such as musculoskeletal diseases." According to Emery, it is now time to look into innovative approaches at Member States' level. National action plans targeting musculoskeletal conditions could be an excellent way of making progress.

The Council invites Member States to "further develop patient-centred policies for health promotion, primary prevention and secondary prevention, treatment and care of chronic diseases." Neil Betteridge, EULAR Vice President PARE (People with Arthritis and Rheumatism in Europe), welcomed this recommendation: "EULAR long ago adopted the call of its patient group members of 'Nothing about us without us', meaning that the sort of collaboration between clinicians and patient representatives recommended in the Council Conclusions is already recognised as a key component of managing rheumatic and musculoskeletal diseases optimally. EULAR can be proud that its own best practice in this respect, as well as in the scientific and research fields, has been identified by ministers across Europe as an essential part of the new framework for managing chronic conditions generally."

The Council Conclusions on "Innovative approaches for chronic diseases in public health and healthcare systems" invite both Member States and the European Commission to discuss and propose actions in the following areas: health promotion and prevention, healthcare management, research into chronic diseases as well as production and exchange of comparable information on chronic diseases across Europe. The European Commission is encouraged to support Member States as well as to prioritize chronic diseases in current and future Europe research and action programs.

Emery welcomed the Council's call to integrate chronic diseases as a priority in European programs: "It is important that EU policy-making sees the longer term needs. The Council's position is in line with EULAR's approach. With a view to the EU 2020 goals, we need to invest strategically in an area like musculoskeletal diseases, where much can be gained in return, in terms of quality of life, but also in terms of economic benefit."

Member States and the European Commission will be called upon to initiate a reflexion process in close dialogue with relevant stakeholders including patients, professionals, healthcare payers and providers, with the aim of optimizing responses to the chronic-disease challenge. The Council Conclusions are an outcome of the work done by the Belgian EU Presidency during its six-month term.

Source: EULAR Press Office, European League Against Rheumatism


Are the goals of the Council similar to those in the US? Leave a comment.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
A panel of 5 cardiovascular experts
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
© 2024 MJH Life Sciences

All rights reserved.